An amended statement of changes in beneficial ownership for James Hippel, Chief Financial Officer of BIO-TECHNE Corp, was filed on November 2, 2026, reporting equity transactions that occurred on August 15, 2026, with the original filing dated August 18, 2026.

Key Highlights

  • Reporting person: James Hippel, CFO of BIO-TECHNE Corp (NASDAQ:TECH)
  • Common stock acquired via vesting (code M): 9,980 shares on August 15, 2026, at $0, bringing direct holdings to 174,694 shares before tax withholding
  • Tax withholding disposition (code F): 4,423 shares of common stock disposed of at $72.4 per share on August 15, 2026, leaving 170,271 shares directly held
  • Performance options: The Board of Directors authorized discretionary vesting for 2,871 performance options on August 15, 2026; the remaining performance options were forfeited, with 34,443 disposed of under code D at an exercise price of $84.61
  • Performance RSUs: The Board authorized discretionary vesting for 1,067 performance restricted stock units; the remaining 12,798 performance RSUs were forfeited on August 15, 2026
  • Restricted stock unit vesting schedule: 4,010 RSUs vested August 15, 2026, with 4,011 remaining to vest August 15, 2027; separately, 4,903 RSUs vested August 15, 2026, with additional tranches due August 15, 2027 and August 15, 2028

James Hippel's August 2026 Equity Transactions at Bio-Techne

According to the amended filing, James Hippel, who serves as Chief Financial Officer at Bio-Techne Corporation, a life-science reagents and instruments company traded on NASDAQ under the symbol TECH, reported multiple equity transactions on August 15, 2026. The filing covers both non-derivative and derivative security activity, including restricted stock unit vestings and the disposition of performance-based awards.

In the non-derivative table, the filing reports that Hippel acquired 9,980 shares of common stock through vesting (transaction code M) at $0, and subsequently had 4,423 shares withheld at $72.4 per share for tax purposes (transaction code F), resulting in a direct beneficial ownership of 170,271 shares following those transactions.

For derivative securities, the filing discloses that the Bio-Techne Board of Directors authorized discretionary vesting for 2,871 performance stock options and 1,067 performance restricted stock units on August 15, 2026, according to the explanation of responses. The remainder of the performance options and performance RSUs were forfeited. The filing further notes that Hippel's remaining restricted stock units are scheduled to vest in tranches on August 15, 2027, and August 15, 2028, as described in footnotes 4 and 5. The amended filing was signed by Andrew Nick as Attorney-in-Fact for James Hippel pursuant to a previously filed Power of Attorney.

What Was Disclosed

This amended ownership statement covers equity award vestings, tax-related share disposals, and performance award forfeitures for Bio-Techne's CFO on August 15, 2026, reflecting changes to direct beneficial ownership and remaining derivative security holdings.